Children

Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Children's Hospital and Stanford

STANFORD, Calif.--(BUSINESS WIRE)--Jun 29, 2007 - The drug mostcommonly used to arrest preterm labor, magnesium sulfate, is morelikely than another common treatment to cause mild to serious sideeffects in pregnant women, according to a study from researchers atLucile Packard Children's Hospital and Stanford University Schoolof Medicine. Their findings suggest that, since the effectivenessof...

Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis

EVRY, France, June 25, 2007 /PRNewswire/ -- Novagali Pharma, anemerging pharmaceutical company specialized in ophthalmologypresents positive results of its pivotal phase III clinical trialpositive results from the Phase III clinical study of Vekacia(R) inchildren suffering from Vernal Keratoconjunctivitis (VKC) at theXIV Afro-Asian Congress of ophthalmology (AACO) held from June 20to 25...

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Bristol-Myers Squibb Company today announced results regarding theefficacy and safety of ORENCIA(R) (abatacept) from the open-labelphase of an ongoing investigational study in children with juvenileidiopathic arthritis (JIA) who have had an inadequate response toone or more disease-modifying anti- rheumatic drugs (DMARDs), suchas m...

Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia

- Results from a Children's Oncology Group (COG) Study Presented atAmerican Society of Clinical Oncology Annual Meeting - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics,Inc. , a biopharmaceutical company focused on developing monoclonalantibodies to treat cancer and other serious diseases, todayannounced that treatment with epratuzumab plus standardchemotherapy is feasible...

Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced today the positive results of studies of theinvestigational medication guanfacine extended release (GXR,previously referred to as SPD503), a selectivealpha-2A-adrenoceptor agonist. These data from two short-term phaseIII placebo-controlled studies and two long-term phase IIIopen-label studies, presented at the 2007 Amer...

Data Show FluMist May Reduce Seasonal Influenza Burden Among Children in School, Daycare Settings

New Economic Analyses of School and Daycare Study Outcomes SuggestVaccinating Against Influenza May Produce Cost Savings forCommunity at Large TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc.announced today research results showing that use of FluMist(R)(Influenza Virus Vaccine Live, Intranasal) in daycare and schoolsettings may help reduce the burden of seasona...

Study Supports Cost-Effectiveness of Medtronic's Spasticity Treatment for Children with Cerebral Palsy

MINNEAPOLIS--(BUSINESS WIRE)--Apr 26, 2007 - A new study publishedin the current issue of the Journal of Child Neurology indicatesthat a treatment from Medtronic, Inc. (NYSE:MDT), for spasticity inchildren with cerebral palsy improves their quality of life and iscost-effective compared to other established cost-effectivetreatments. The findings of this Medtronic-sponsored study shouldexpand...

Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter

BOSTON, April 25, 2007 /PRNewswire-USNewswire/ -- At leastone-third of the time, the symptoms of bipolar disorder firstappear in childhood or adolescence. However, in children, it can bedifficult to distinguish bipolar symptoms from those of otherdisorders, notes the May 2007 issue of the Harvard Mental HealthLetter. Children, especially young children, usually do not show theadul...

Study Shows Children With ADHD Who Start on Strattera are More Likely to Change Therapies

Prime Therapeutics recommends clinical utilization managementprograms ST. PAUL, Minn., April 10, 2007 /PRNewswire/ -- Pharmacy benefitmanager Prime Therapeutics (Prime) today announced the results of astudy on the utilization of Strattera(R) (atomoxetine) for treatingattention deficit hyperactivity disorder (ADHD) in children. Thestudy found that children who start on Strattera were 4.2 t...